Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: Glenn D. Rudolph who wrote (424)	7/7/1998 1:30:00 AM
From: Thomas M.	Read Replies (1) \| Respond to of 1154

The stock ticked up nicely today, on the release of the quarterly report. I saw nothing noteworthy in the report. Revenues are shifting from government grants to corporate-based, as expected. Tom

To: Glenn D. Rudolph who wrote (424)	7/7/1998 1:44:00 AM
From: Larry Liebman	Read Replies (1) \| Respond to of 1154

Interesting speculation. GENE has some 18 million shares out with some $40 million in cash. Deals with pharma are $100 million+. R & D is on track for $30 million+ per annum. Stock at $5 has a net value of $90 million. Take away cash and you value the technology at $50 million. The company employs around 250 people. I have a small position at $8. The second and third tier biotechs have been battered. I suggest they offer excellent value at this point- though those of us with friends in Yahoo or Amazon will derive little satisfaction from that point!